Beyond Monotherapy: Unlocking the Promise of Combination Therapies

8 October 2025.

From Monotherapy to Synergy: The Strategic Shift

The move from monotherapy to combination therapy marks a pivotal change in how medicine addresses complex diseases. While monotherapies target single pathways, their impact is often limited in multifactorial conditions such as cancer, autoimmune disease, and infectious disorders.

Combination therapies, by contrast, align multiple mechanisms of action, creating synergistic effects that improve outcomes and reduce treatment resistance. This approach reflects a growing recognition that disease is dynamic, adaptive, and individualised rather than linear or isolated.

Why the shift matters:

Enables clinicians to target overlapping biological mechanisms simultaneously
Reduces drug resistance and enhances therapeutic durability
Supports tailored regimens based on molecular profiles and disease stage
Advances precision medicine by combining complementary therapeutic modes

Genetic diversity, immune response variability, and comorbidities further amplify the need for customised regimens. Whether pairing immunotherapies with targeted agents in oncology or layering antivirals in HIV management, combination therapy exemplifies a shift from single-solution treatment to a strategic reimagining of precision care.

Visiongain Analyst Insight: As clinical complexity rises, combination therapy strategies are no longer optional; they are becoming essential for next-generation pipelines. Companies that can integrate molecular profiling, adaptive trials, and real-world data into their design and validation will lead in both clinical efficacy and market access.

Regulatory Evolution: Enabling Synergistic Innovation

Global regulatory frameworks are evolving rapidly to keep pace with the complexity of combination therapies. Agencies such as the FDA, EMA, and CDSCO are adopting adaptive trial designs, rolling submissions, and biomarker-driven endpoints to assess multi-agent regimens more efficiently.

Traditional linear approval pathways are proving too rigid for therapies that address multifactorial diseases such as oncology, autoimmune, and rare disorders. Regulators are now facilitating earlier engagement, cross-trial data sharing, and greater reliance on real-world evidence to accelerate review cycles without compromising safety or efficacy.

Key trends shaping regulatory transformation:

Adoption of adaptive and master protocols to assess multiple agents simultaneously
Use of real-world evidence and biomarker endpoints to speed evaluation
Rolling submissions that enable faster approvals and post-market adaptation
Growing harmonisation through initiatives like Project Orbis and ICMRA
Broader collaboration between regulators, CROs, and industry to reduce duplication and cost

For CROs and CDMOs, this shift is opening new opportunities in adaptive design support, multi-arm trial execution, and data integration, allowing them to serve complex combination pipelines with speed and scale.

Visiongain Analyst Insight: The convergence of regulatory agility and therapeutic innovation is redefining competitive advantage. Sponsors that integrate regulatory strategy into early R&D, including companion diagnostics and digital endpoints, will achieve faster approvals and stronger payer confidence, positioning themselves as trusted partners in a rapidly modernising global regulatory landscape.

Rise of Co-Investment Models: Redefining Collaboration

Commercial frameworks are being reshaped to match the complexity of combination therapy development. Traditional siloed models are giving way to co-investment partnerships, uniting pharma companies, CROs, and biotech innovators around shared assets and risk-balanced portfolios.

Why co-investment is gaining momentum:

Shared risk and capital across development, reducing single-company exposure
Accelerated time-to-market through joint trial networks and data platforms
Expanded global reach via cross-border regulatory and marketing alliances
Integrated IP and pricing models supporting dynamic market entry
Stronger innovation pipelines, blending large pharma scale with biotech agility

This shift is most visible in oncology, where major collaborations are driving cross-platform development:

Merck and Eisai: co-developing and commercialising Keytruda + Lenvima across multiple tumour types.
Gilead and Arcus Biosciences: a US$2 billion collaboration to accelerate immunotherapy combinations for lung and GI cancers.
Vertex Pharmaceuticals and CRISPR Therapeutics: investing in gene-editing + small-molecule combinations for sickle cell and beta-thalassaemia.

CROs such as IQVIA and Parexel are also enabling multi-arm trial designs for HIV and TB therapies, integrating antivirals and immunomodulators in parallel cohorts.

Visiongain Analyst Insight: The era of isolated molecule development is ending. Strategic partnerships that combine scientific depth, regulatory expertise, and commercial scale will dominate the next wave of combination innovation, setting a new standard for speed, scalability, and shareholder value in biopharma alliances.

Key Collaborations and Acquisitions Making Headlines

Merck & Co. (Nov 2024): Licensed LM-299, a PD-1/VEGF bispecific antibody from LaNova Medicines in a US$3.3 billion deal. The asset combines checkpoint inhibition and anti-angiogenesis, reinforcing Merck’s position in combination oncology.
Novartis AG (Nov 2024): Acquired MorphoSys AG for US$2.9 billion, adding assets including Monjuvi® (CD19 + lenalidomide) and Pelabresib (BET inhibitor + ruxolitinib), strengthening its haematology and immuno-oncology franchise.
Novo Holdings (Feb 2024): Acquired Catalent Inc. for US$16.5 billion, expanding biologics, gene therapy, and combination manufacturing capabilities across Novo’s global network.
Gilead Sciences (Jan 2024): Deepened its partnership with Arcus Biosciences in a US$2 billion expansion to advance multi-agent immunotherapy regimens targeting NSCLC and gastrointestinal cancers.

Visiongain Analyst Insight: M&A activity reflects a decisive shift toward multi-modality platforms that integrate biologics, small molecules, and gene therapies under unified manufacturing and regulatory strategies, accelerating the creation of end-to-end ecosystems that can deliver both therapeutic and commercial scale.

Recent Product Launches

Novo Nordisk (Mar 2025): Launched CagriSema, a fixed-dose combination of cagrilintide and semaglutide for obesity and type 2 diabetes. The therapy targets appetite and glucose control simultaneously, outperforming single-agent regimens.
Bristol Myers Squibb (May 2025): Introduced Cobenfy™ (KarXT), combining xanomeline and trospium for schizophrenia and Alzheimer’s-related psychosis, the first major mechanistic innovation in CNS treatment in over three decades.
Gilead & Merck Co. (Jun 2025): Launched Trodelvy® + Keytruda® for PD-L1–positive metastatic triple-negative breast cancer, the first approved regimen to pair a TROP2-directed ADC with a PD-1 checkpoint inhibitor, achieving a PFS improvement from 7.8 to 11.2 months in Phase III.

Visiongain Analyst Insight: These launches mark a new benchmark in modern therapeutics. Combination therapies are no longer experimental; they are defining the clinical standard for efficacy, safety, and personalised care. This evolution will reshape treatment design, reimbursement frameworks, and patient expectations throughout the coming decade.

Market Outlook: Combination Therapies Redefining Clinical and Commercial Strategy

Combination therapies are shifting from experimental innovation to a central pillar of precision medicine. As monotherapies reach their limits, multi-agent regimens are proving vital to improving efficacy, reducing resistance, and broadening patient access.

The market is being reshaped by convergence, pharma with biotech, small molecules with biologics, and regulators with developers through adaptive approval models. Growth is accelerating across oncology, metabolic disease, and neuropsychiatry, supported by platform-based R&D and AI-driven trial design.

Visiongain projects sustained momentum, driven by:

Regulatory recognition of adaptive and real-world evidence frameworks
Co-investment models de-risking late-stage development
Rising demand for personalised, multi-target treatment strategies
Expanded combination manufacturing capabilities across CDMOs

Visiongain Analyst Insight: Combination therapies are emerging as the cornerstone of competitive advantage. Companies that integrate scientific synergy with scalable manufacturing, regulatory transparency, and payer-ready models will define the next decade of precision medicine. This approach will transform today’s innovations into the infrastructure needed for global healthcare in the coming decade.

Strategic Questions for Executives

Regulatory and Clinical Readiness: Are your combination therapy programmes designed for adaptive approval models and backed by robust clinical validation that builds clinician and payer confidence?
Partnership and Platform Strategy: How are you leveraging co-investment and CRO/CDMO partnerships to accelerate development, share risk, and scale multi-agent pipelines globally?
Commercial and Market Access Alignment: Do your pricing, manufacturing, and reimbursement strategies align with the new economics of combination therapies, where value depends on synergy rather than standalone performance?

What’s Next from Visiongain

At Visiongain, we analyse these market shifts with precision and depth. Our reports combine robust data, expert interpretation, and strategic foresight, empowering healthcare leaders to anticipate change and act decisively.

Download samples of our latest reports :